8-K: Applied DNA Sciences Faces Nasdaq Delisting Threat Over Bid Price, Seeks Hearing

Applied DNA Sciences, Inc. received a delisting notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement and has requested a hearing to appeal the decision, which stays immediate delisting.

Summary

• Applied DNA Sciences, Inc. (APDN) received a written notice from Nasdaq on May 30, 2025, indicating non-compliance with the minimum $1.00 bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
• The non-compliance was due to the company's common stock closing below $1.00 per share for 32 consecutive business days, from April 14, 2025, to May 29, 2025.
• The company previously effected a 1-for-15 reverse stock split on June 2, 2025, in an attempt to regain compliance, which typically requires a closing bid price of at least $1.00 for 10 to 20 consecutive business days.
• However, Nasdaq informed the company that it is not eligible for a standard compliance period under Rule 5810(c)(3)(A)(iv) due to prior reverse stock splits within the last one to two years with a cumulative ratio of 250:1 or more.
• Consequently, the company's securities are subject to delisting from Nasdaq.
• Applied DNA Sciences has timely requested a hearing before the Nasdaq Hearings Panel, which will stay any further suspension or delisting action pending the conclusion of the hearing process.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's failure to meet Nasdaq's minimum bid price requirement and the subsequent delisting notice. While the company has requested a hearing, the ineligibility for a standard compliance period and the uncertainty of the hearing outcome present significant risks to its continued listing and investor confidence.

Positives

• The company has timely requested a hearing with the Nasdaq Hearings Panel, which temporarily stays any further suspension or delisting action.
• The company previously effected a 1-for-15 reverse stock split in an effort to regain compliance with the bid price rule.

Negatives

• Applied DNA Sciences failed to satisfy Nasdaq's $1.00 minimum bid price requirement for 32 consecutive business days.
• The company is not eligible for a standard compliance period due to previous reverse stock splits, making delisting a more immediate threat.
• The company's securities are subject to delisting from Nasdaq.

Risks

• There is no assurance that the Nasdaq Hearings Panel will grant the company's request for continued listing.
• There is no assurance that the company will be able to regain compliance with Nasdaq's listing rules.
• There is a risk that the company may not be able to maintain its listing on Nasdaq.

Future Outlook

The company intends to regain compliance with the Bid Price Rule and maintain its listing on Nasdaq, but there is no assurance regarding the outcome of the Nasdaq hearing and appeal process.

Management Comments

• All forward-looking statements reflect the Company’s beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
• James A. Hayward, Chief Executive Officer, signed the report on behalf of Applied DNA Sciences, Inc.

Industry Context

Companies listed on major exchanges like Nasdaq are subject to strict listing requirements, including minimum bid prices. Failure to meet these often leads to delisting notices. Reverse stock splits are a common strategy employed by companies to increase their share price and regain compliance, but repeated use or large cumulative ratios can lead to ineligibility for standard compliance periods, as seen in this case. This highlights the challenges smaller or struggling companies face in maintaining exchange listings.

Comparison to Industry Standards

• This document does not provide specific financial or operational results that can be directly compared to industry benchmarks or specific comparable companies/projects.
• The issue is purely regulatory compliance related to stock price, a common challenge for companies whose stock trades below $1.00.
• The key differentiator here is the ineligibility for a standard compliance period due to prior reverse splits, which is a more severe situation than a typical bid price deficiency and less common among well-performing companies.

Corporate Governance

Legal Proceedings

• The company has requested a hearing before the Nasdaq Hearings Panel to appeal the delisting notice, which is a regulatory proceeding.

Stakeholder Impact

• Shareholders: Face potential delisting of common stock from Nasdaq, which could significantly impact liquidity and valuation. The reverse stock split also reduces the number of shares outstanding, which can be perceived negatively.
• Employees: Potential uncertainty regarding the company's future if delisting occurs.
• Creditors: May view the company as higher risk due to listing issues.

Next Steps

• The company will proceed with a hearing before the Nasdaq Hearings Panel.
• The company must evidence a closing bid price of at least $1.00 per share for a minimum of ten, but generally not more than twenty, consecutive business days to regain compliance, if granted the opportunity by the Panel.

Key Dates

Recommendation

Keywords

Applied DNA Sciences, APDN, Nasdaq, delisting, bid price requirement, reverse stock split, Nasdaq Listing Rule 5550(a)(2), Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq Hearings Panel, stock market, compliance, corporate governance